Lazard Asset Management
CRBU icon

Lazard Asset Management’s Caribou Biosciences CRBU Stock Holding History

Lazard Asset Management’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-298
Closed – – 2346
2024
Q4 		$0 Hold
298
– – ﹤0.01% 2325
2024
Q3 		$0 Sell
298
-132
-31% -$270 ﹤0.01% 2296
2024
Q2 		$0 Sell
430
-3,791
-90% -$12.1K ﹤0.01% 2261
2024
Q1 		$20K Sell
4,221
-17,068
-80% -$105K ﹤0.01% 1839
2023
Q4 		$121K Buy
21,289
+16,637
+358% +$82.2K ﹤0.01% 1584
2023
Q3 		$21K Buy
4,652
+188
+4% +$1.17K ﹤0.01% 2087
2023
Q2 		$18K Buy
4,464
+55
+1% +$247 ﹤0.01% 2113
2023
Q1 		$22K Buy
4,409
+3,092
+235% +$19.3K ﹤0.01% 2033
2022
Q4 		$8K Buy
+1,317
New +$11.7K ﹤0.01% 2215

Other funds holding CRBU

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Lazard Asset Management's CRBU Position: Q1 2025 in Review

Lazard Asset Management sold out of Caribou Biosciences (CRBU) in Q1 2025, closing a stake of 298 shares.

Lazard Asset Management first reported a position in CRBU in Q4 2022 and held it in 9 quarters. The position peaked at $121K in Q4 2023. 131 funds tracked by Wall St. Rank hold CRBU as of Q1 2025.

  • Lazard Asset Management reported no remaining Caribou Biosciences position as of Q1 2025 after selling out during the quarter.
  • Lazard Asset Management sold 298 Caribou Biosciences shares in Q1 2025.
  • Lazard Asset Management first reported a position in Caribou Biosciences in Q4 2022 and held it in 9 quarters.
  • Lazard Asset Management's Caribou Biosciences position peaked at $121K in Q4 2023.
  • 131 funds tracked by Wall St. Rank held Caribou Biosciences as of Q1 2025.

Based on Lazard Asset Management's 13F filing for Q1 2025, filed 15 May 2025.